Stock Scorer

Citius Oncology, Inc. (CTOR)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 1.5M 3M 4.5M Q4 '25: 3.9M Q1 '26: 1.7M Q2 '26: 1.5M Q4 '25 Q1 '26 Q2 '26

Gross Profit Quarterly

0 1.5M 3M 4.5M Q4 '25: 3.2M Q1 '26: 1.3M Q2 '26: 1M Q4 '25 Q1 '26 Q2 '26

Operating Income Quarterly

-30M -20M -10M 0 10M 20M 30M Q1 '23: -147.9K Q2 '23: -199.6K Q3 '23: -421.5K Q4 '23: -244.1K Q1 '24: -268.4K Q2 '24: -4.6M Q3 '24: -6.7M Q4 '24: -6.4M Q1 '25: -7.5M Q2 '25: -4.9M Q3 '25: -4.7M Q4 '25: -5.3M Q1 '26: -28.6M Q2 '26: -8.7M Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Net Income Quarterly

-30M -20M -10M 0 10M 20M 30M Q2 '21: -724 Q4 '21: 0 Q1 '23: 611.7K Q2 '23: 616.3K Q3 '23: 157.9K Q4 '23: -4.7M Q1 '24: -4.8M Q2 '24: -4.8M Q3 '24: -6.8M Q4 '24: -6.7M Q1 '25: -7.7M Q2 '25: -5.4M Q3 '25: -5M Q4 '25: -5.5M Q1 '26: -26.6M Q2 '26: -8.9M Q4 '21 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Cost of Revenue Quarterly

0 300K 600K 900K Q4 '25: 789.2K Q1 '26: 328.9K Q2 '26: 491.8K Q4 '25 Q1 '26 Q2 '26

Operating Cash Flow Quarterly

-9M -6M -3M 0 3M 6M 9M Q1 '23: -168.8K Q2 '23: -100.3K Q3 '23: -113.5K Q4 '23: -218.8K Q1 '24: -191.7K Q2 '24: -366.1K Q4 '25: -7.4M Q1 '26: -3.8M Q2 '26: -2.7M Q1 '23 Q3 '23 Q1 '24 Q4 '25 Q2 '26

Shares Outstanding Quarterly

0 40M 80M 120M Q3 '21: 1.5M Q1 '22: 1.7M Q2 '22: 1.5M Q3 '22: 1.5M Q1 '23: 6.6M Q2 '23: 6.6M Q3 '23: 6.6M Q4 '23: 67.5M Q1 '24: 67.5M Q2 '24: 67.5M Q4 '24: 71.6M Q1 '25: 71.6M Q2 '25: 71.6M Q4 '25: 87.5M Q1 '26: 100M Q2 '26: 107.9M Q1 '22 Q3 '22 Q2 '23 Q4 '23 Q2 '24 Q1 '25 Q4 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.60 -0.40 -0.20 0.00 0.20 0.40 0.60 Q2 '22: 0.00 Q3 '22: 0.00 Q4 '22: 0.12 Q1 '23: 0.19 Q2 '23: 0.26 Q3 '23: 0.28 Q4 '23: 0.09 Q1 '24: -0.05 Q2 '24: -0.19 Q3 '24: -0.31 Q4 '24: -0.33 Q1 '25: -0.37 Q2 '25: -0.38 Q3 '25: -0.34 Q4 '25: -0.31 Q1 '26: -0.47 Q2 '26: -0.47 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for CTOR: Free Cash Flow. Nothing in this filer's XBRL supports it for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.